-
Mashup Score: 4
64 Background: LACOG0415 is a 3-arm randomized trial evaluating ADT with abiraterone acetate plus prednisone (ADT+AAP), apalutamide alone (APA) or apalutamide with AAP (APA+AAP) for patients with locally-advanced, high-risk biochemical recurrence or metastatic castration-sensitive prostate cancer (ASCO 2020). In this trial, ADT+AAP and APA+AAP achieved the primary endpoint of percentage of…
Source: Journal of Clinical OncologyCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 2Knowledge, attitudes, and practices of active surveillance in prostate cancer among urologists: a real-life survey from Brazil - PubMed - 3 year(s) ago
Not applicable.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Happy to share our work lead by @wroclawski_uro with the largest survey worldwide and the first in Brazil evaluating how AS is used in Brazil. Only 53% of urologists use AS for very low and low risk PC. Medical and patient education are needed. https://t.co/vgGPRLcf7X https://t.co/8ysAzVqaZK
-
-
Mashup Score: 3
Jonathan Rosenberg gives an overview of the current landscape.
Source: AnchorCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @Uromigos: Efficacy and adverse events with ADCs in advanced urothelial cancer with @DrRosenbergMSK https://t.co/SmqWdekjp6
-
-
Mashup Score: 3
: Nivolumab, a PD-1 ICI has been recently approved for the adjuvant treatment of MIUC patients. However, conflicting data from another randomized tria…
Source: www.sciencedirect.comCategories: Latest Headlines, Oncologists2Tweet-
Should all high risk UC patients receive ICI as adjuvant therapy? Is there any subgroup with higher benefit? Is there a subset of patients who should not receive? Just out our meta-analysis @drenriquegrande @DrAndreFay @fsabino_onco @tompowles1 @sonpavde https://t.co/LUgupIAR9l
-
-
Mashup Score: 0
Androgen deprivation therapy (ADT) combined with apalutamide, abiraterone acetate plus prednisone, enzalutamide, or docetaxel are the standard treatme…
Source: www.sciencedirect.comCategories: Latest Headlines, UrologyTweet-
We must test more for this “simple”strategy to “SPARE” costs and maybe toxicity. Our trial did the same in the sensitive setting https://t.co/VKn76I0Uw3 https://t.co/u6LxpTtj99
-
-
Mashup Score: 1Inscrição Eventos 2022 - Cobertura ASCO GU 2022 - 3 year(s) ago
Inscrição Eventos 2022 – Cobertura ASCO GU 2022Sign in to Google to save your progress. Learn moreNome Completo *Email *CPF *Empresa *Cargo *CRM *Celular com DDD *Você autoriza a gravação do programa na qual pode ocorrer a aparição da sua imagem? *SimSubmitClear formNever submit passwords through Google Forms.
Source: Google DocsCategories: Hem/Oncs, Latest HeadlinesTweet-
Amazing post #GU22 @ASCO lead by @OncologyBio. Pleasure to be with you @neerajaiims @PGrivasMDPhD @FabioSchutz78 @DrAndreFay @adrigons @fsabino_onco @igorpmorbeck @asasse. Free subscriptions: https://t.co/oMz36QCYro https://t.co/BnZRSghVti
-
-
Mashup Score: 1PBRM1 Mutations as a Predictive Biomarker for Immunotherapy in Metastatic Renal Cell Carcinoma: A Systematic Review - IOS Press - 3 year(s) ago
INTRODUCTION: Genomic features linked to prediction of response to immunotherapy in metastatic renal cell carcinoma (mRCC) are still lacking. Protein polybromo-1 (PBRM1) mutations have been studied as a potential biomarker of clinical benefit, with c
Source: content.iospress.comCategories: Latest Headlines, Oncologists2Tweet-
Outstanding work and very promising to better understand the role of PBRM1 mutations in ccRCC. But our systematic review did not show good correlation between PBRM1 mutations and response to ICI in clinical practice. There are several issues to be adressed https://t.co/udCNw3karg https://t.co/8MzZlMJSFZ
-
-
Mashup Score: 0
64 Background: LACOG0415 is a 3-arm randomized trial evaluating ADT with abiraterone acetate plus prednisone (ADT+AAP), apalutamide alone (APA) or apalutamide with AAP (APA+AAP) for patients with locally-advanced, high-risk biochemical recurrence or metastatic castration-sensitive prostate cancer (ASCO 2020). In this trial, ADT+AAP and APA+AAP achieved the primary endpoint of percentage of…
Source: Journal of Clinical OncologyCategories: Latest Headlines, UrologyTweet-
@Prof_Nick_James There are some caveats, but in general ADT free alternatives were not better, even with higher levels of testosterone https://t.co/Gl6tbVoI0q
-
-
Mashup Score: 0V SIMPÓSIO INTERNACIONAL GU-REVIEW 2021 - LACOG - 3 year(s) ago
Programação
Source: www.geniturinariobrasil.com.brCategories: Latest Headlines, Oncologists2Tweet-
Starting today! Subscribe free: https://t.co/PVrbbmzhII. Outstanding speakers @TiansterZhang @ERPlimackMD @montypal @neerajaiims @DrSpratticus @EfstathiouEleni @drenriquegrande @tompowles1 https://t.co/qpGfyUgjuc
-
-
Mashup Score: 0
Androgen deprivation therapy (ADT) combined with apalutamide, abiraterone acetate plus prednisone, enzalutamide, or docetaxel are the standard treatme…
Source: www.sciencedirect.comCategories: Latest Headlines, Oncologists2Tweet-
KUDOS to @Lacog_group, amazing work. Interesting phase 2 trial looking at ADT free alternatives for patients with prostate cancer. Thank you and congrats to all authors https://t.co/VKn76I0Uw3
-
@scserendipity1 @JonathanVermaMD @neerajaiims @JAMAOnc @OncoAlert @urotoday @dr_coops @Huntsman_GU @cdanicas @GGiannarini @AzadOncology @montypal @nsayeghmd @BogdanaSchmidt @ADesaiMD I understand your point but the use of an ARSi without ADT did not show a QoL benefit over an ADT alone or in combination. We showed this https://t.co/Gl6tbVoI0q and even in the trial the patients have worst sexual and physical function